Paul Choi
Stock Analyst at Goldman Sachs
(3.55)
# 843
Out of 4,876 analysts
109
Total ratings
53.52%
Success rate
4.55%
Average return
Main Sectors:
Stocks Rated by Paul Choi
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AMRN Amarin Corporation | Maintains: Sell | $7 → $12 | $15.71 | -23.62% | 9 | Jun 25, 2025 | |
| URGN UroGen Pharma | Maintains: Neutral | $16 → $3 | $13.47 | -77.73% | 4 | May 22, 2025 | |
| GOSS Gossamer Bio | Maintains: Buy | $7 → $8 | $1.25 | +540.00% | 6 | May 16, 2025 | |
| PHAT Phathom Pharmaceuticals | Maintains: Neutral | $10 → $5 | $9.73 | -48.59% | 10 | May 2, 2025 | |
| ARVN Arvinas | Maintains: Neutral | $12 → $8 | $7.54 | +6.10% | 3 | May 2, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Buy | $60 → $52 | $32.40 | +60.49% | 2 | Apr 17, 2025 | |
| VIR Vir Biotechnology | Maintains: Buy | $28 → $21 | $5.16 | +306.98% | 8 | Apr 17, 2025 | |
| RGNX REGENXBIO | Maintains: Neutral | $14 → $12 | $8.40 | +42.86% | 3 | Apr 17, 2025 | |
| ESPR Esperion Therapeutics | Maintains: Neutral | $4 → $3 | $0.99 | +201.93% | 9 | Apr 17, 2025 | |
| DVAX Dynavax Technologies | Maintains: Sell | $12 → $10 | $9.91 | +0.91% | 4 | Apr 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $225 | $172.14 | +30.71% | 4 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $143 | $81.49 | +75.48% | 1 | Dec 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $32 → $42 | $49.81 | -15.68% | 7 | Dec 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $85 → $60 | $33.16 | +80.94% | 2 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $17 → $19 | $15.09 | +25.91% | 6 | Aug 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $32 | $28.04 | +14.12% | 1 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $29 → $50 | $44.86 | +11.46% | 6 | Jul 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 → $19 | $4.85 | +291.75% | 3 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $400 → $50 | $5.22 | +857.85% | 7 | Jun 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $25 | $1.05 | +2,280.95% | 3 | May 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $151 → $170 | $14.09 | +1,106.53% | 2 | Oct 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Sell | $9 → $8 | $3.33 | +140.60% | 4 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $33 | $29.63 | +11.37% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $112 | $46.99 | +138.37% | 1 | Mar 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $135 | $125.42 | +7.64% | 1 | Jun 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $270 → $300 | $25.76 | +1,064.60% | 2 | Mar 30, 2020 |
Amarin Corporation
Jun 25, 2025
Maintains: Sell
Price Target: $7 → $12
Current: $15.71
Upside: -23.62%
UroGen Pharma
May 22, 2025
Maintains: Neutral
Price Target: $16 → $3
Current: $13.47
Upside: -77.73%
Gossamer Bio
May 16, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $1.25
Upside: +540.00%
Phathom Pharmaceuticals
May 2, 2025
Maintains: Neutral
Price Target: $10 → $5
Current: $9.73
Upside: -48.59%
Arvinas
May 2, 2025
Maintains: Neutral
Price Target: $12 → $8
Current: $7.54
Upside: +6.10%
Xenon Pharmaceuticals
Apr 17, 2025
Maintains: Buy
Price Target: $60 → $52
Current: $32.40
Upside: +60.49%
Vir Biotechnology
Apr 17, 2025
Maintains: Buy
Price Target: $28 → $21
Current: $5.16
Upside: +306.98%
REGENXBIO
Apr 17, 2025
Maintains: Neutral
Price Target: $14 → $12
Current: $8.40
Upside: +42.86%
Esperion Therapeutics
Apr 17, 2025
Maintains: Neutral
Price Target: $4 → $3
Current: $0.99
Upside: +201.93%
Dynavax Technologies
Apr 17, 2025
Maintains: Sell
Price Target: $12 → $10
Current: $9.91
Upside: +0.91%
Feb 13, 2025
Maintains: Buy
Price Target: $200 → $225
Current: $172.14
Upside: +30.71%
Dec 18, 2024
Initiates: Buy
Price Target: $143
Current: $81.49
Upside: +75.48%
Dec 4, 2024
Maintains: Sell
Price Target: $32 → $42
Current: $49.81
Upside: -15.68%
Aug 13, 2024
Downgrades: Neutral
Price Target: $85 → $60
Current: $33.16
Upside: +80.94%
Aug 1, 2024
Maintains: Neutral
Price Target: $17 → $19
Current: $15.09
Upside: +25.91%
Jul 26, 2023
Maintains: Buy
Price Target: $22 → $32
Current: $28.04
Upside: +14.12%
Jul 18, 2023
Maintains: Buy
Price Target: $29 → $50
Current: $44.86
Upside: +11.46%
Jun 29, 2023
Maintains: Buy
Price Target: $21 → $19
Current: $4.85
Upside: +291.75%
Jun 27, 2023
Maintains: Sell
Price Target: $400 → $50
Current: $5.22
Upside: +857.85%
May 24, 2022
Maintains: Buy
Price Target: $43 → $25
Current: $1.05
Upside: +2,280.95%
Oct 6, 2021
Maintains: Buy
Price Target: $151 → $170
Current: $14.09
Upside: +1,106.53%
Aug 6, 2021
Maintains: Sell
Price Target: $9 → $8
Current: $3.33
Upside: +140.60%
Mar 22, 2021
Assumes: Buy
Price Target: $33
Current: $29.63
Upside: +11.37%
Mar 22, 2021
Assumes: Buy
Price Target: $112
Current: $46.99
Upside: +138.37%
Jun 29, 2020
Downgrades: Neutral
Price Target: $135
Current: $125.42
Upside: +7.64%
Mar 30, 2020
Upgrades: Neutral
Price Target: $270 → $300
Current: $25.76
Upside: +1,064.60%